BAJAJ BROKING

Notification
No new Notification messages
Tankup Engineers IPO is Open!
Apply for the Tankup Engineers IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

5265

543322

ALIVUS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ALIVUS LIFE SCIENCES LTD performance

Today’s low

Today’s high

₹ 996.50 ₹ 1034.10
₹ 1015.40

52 week low

52 week high

₹ 743.85 ₹ 1335.10
₹ 1015.40

Open Price

₹ 1033.60

Prev. Close

₹ 1033.60

Volume (Shares)

19444.00

Total traded value

₹ 197.43

Upper Circuit

₹ 1240.30

Lower Circuit

₹ 826.90

info

ALIVUS LIFE SCIENCES LTD Share Price Update

As of the latest trading session, ALIVUS LIFE SCIENCES LTD share price is currently at ₹ 1023.9, which is down by -9.69 from its previous closing. Today, the stock has fluctuated between ₹ 996.50 and ₹ 1034.10. Over the past year, ALIVUS LIFE SCIENCES LTD has achieved a return of 23.63 %. In the last month alone, the return has been -3.24 %. Read More...

ALIVUS LIFE SCIENCES LTD fundamentals


  • Market cap (Cr)

    12,390.90

  • P/E Ratio (TTM)

    28.58

  • Beta

    0.56

  • Book Value / share

    207.16

  • Return on equity

    21.07%

  • EPS (TTM)

    36.05

  • Dividend yield

    2.18%

  • Net profit/quarter (Cr)

    136.96

info icon alternate text
  • Market cap (Cr)

    12,259.80

  • P/E Ratio (TTM)

    28.58

  • Beta

    0.50

  • Book Value / share

    207.16

  • Return on equity

    21.07%

  • EPS (TTM)

    36.05

  • Dividend yield

    2.18%

  • Net profit/quarter (Cr)

    136.96

info icon alternate text

ALIVUS LIFE SCIENCES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 641.84
Operating Expense 467.15
Net Profit 136.96
Net Profit Margin (%) 21.33
Earnings Per Share (EPS) 11.18
EBITDA 200.77
Effective Tax Rate (%) 26.02
Particulars SEP 2024 (Values in Cr)
Revenue 506.88
Operating Expense 387.95
Net Profit 95.32
Net Profit Margin (%) 18.80
Earnings Per Share (EPS) 7.78
EBITDA 142.89
Effective Tax Rate (%) 25.21
Particulars JUN 2024 (Values in Cr)
Revenue 588.62
Operating Expense 443.87
Net Profit 111.48
Net Profit Margin (%) 18.93
Earnings Per Share (EPS) 9.10
EBITDA 164.98
Effective Tax Rate (%) 25.79
Particulars MAR 2024 (Values in Cr)
Revenue 536.60
Operating Expense 410.05
Net Profit 97.94
Net Profit Margin (%) 18.25
Earnings Per Share (EPS) 7.99
EBITDA 144.57
Effective Tax Rate (%) 24.47
Particulars DEC 2023 (Values in Cr)
Revenue 572.80
Operating Expense 413.82
Net Profit 118.77
Net Profit Margin (%) 20.73
Earnings Per Share (EPS) 9.69
EBITDA 174.25
Effective Tax Rate (%) 26.08
Particulars MAR 2024 (Values in Cr)
Revenue 2283.21
Operating Expense 1663.97
Net Profit 470.89
Net Profit Margin (%) 20.62
Earnings Per Share (EPS) 38.43
EBITDA 686.29
Effective Tax Rate (%) 25.40
Particulars MAR 2023 (Values in Cr)
Revenue 2161.22
Operating Expense 1561.57
Net Profit 466.96
Net Profit Margin (%) 21.60
Earnings Per Share (EPS) 38.11
EBITDA 671.25
Effective Tax Rate (%) 25.71
Particulars MAR 2022 (Values in Cr)
Revenue 2123.21
Operating Expense 1572.99
Net Profit 418.72
Net Profit Margin (%) 19.72
Earnings Per Share (EPS) 35.63
EBITDA 630.77
Effective Tax Rate (%) 25.87
Particulars MAR 2021 (Values in Cr)
Revenue 1885.17
Operating Expense 1415.04
Net Profit 351.58
Net Profit Margin (%) 18.64
Earnings Per Share (EPS) 32.61
EBITDA 591.88
Effective Tax Rate (%) 25.34
Particulars MAR 2020 (Values in Cr)
Revenue 1537.31
Operating Expense 1128.24
Net Profit 313.10
Net Profit Margin (%) 20.36
Earnings Per Share (EPS) 29.04
EBITDA 483.96
Effective Tax Rate (%) 25.64
Particulars MAR 2024 (Values in Cr)
Book Value / Share 190.35
ROE % 21.07
ROCE % 27.94
Total Debt to Total Equity 0.01
EBITDA Margin 30.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 174.51
ROE % 22.28
ROCE % 29.80
Total Debt to Total Equity 0.01
EBITDA Margin 31.06
Particulars MAR 2022 (Values in Cr)
Book Value / Share 167.66
ROE % 29.83
ROCE % 42.20
Total Debt to Total Equity 0.00
EBITDA Margin 29.71
Particulars MAR 2021 (Values in Cr)
Book Value / Share 768.11
ROE % 60.91
ROCE % 96.75
Total Debt to Total Equity 0.00
EBITDA Margin 31.40
Particulars MAR 2020 (Values in Cr)
Book Value / Share 2049.45
ROE % 127.84
ROCE % 185.60
Total Debt to Total Equity 0.00
EBITDA Margin 31.48
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 301.59
Total Assets 2850.41
Total Liabilities 2850.41
Total Equity 2332.32
Share Outstanding 122527172
Price to Book Ratio 4.07
Return on Assets (%) 16.51
Return on Capital (%) 20.19
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 309.39
Total Assets 2702.14
Total Liabilities 2702.14
Total Equity 2138.20
Share Outstanding 122527172
Price to Book Ratio 2.24
Return on Assets (%) 17.28
Return on Capital (%) 21.84
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 512.16
Total Assets 2471.00
Total Liabilities 2471.00
Total Equity 2054.31
Share Outstanding 122527172
Price to Book Ratio 2.74
Return on Assets (%) 16.94
Return on Capital (%) 20.38
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 115.59
Total Assets 1997.07
Total Liabilities 1997.07
Total Equity 752.74
Share Outstanding 9800450
Price to Book Ratio 0.00
Return on Assets (%) 17.60
Return on Capital (%) 46.71
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 9.99
Total Assets 1725.60
Total Liabilities 1725.60
Total Equity 401.69
Share Outstanding 1960090
Price to Book Ratio 0.00
Return on Assets (%) 18.14
Return on Capital (%) 77.94
Particulars MAR 2024 (Values in Cr)
Net Income 631.29
Cash from Operations 576.47
Cash from Investing -116.48
Cash from Financing -279.44
Net change in Cash 17.59
Free Cash Flow 705.44
Particulars MAR 2023 (Values in Cr)
Net Income 628.60
Cash from Operations 459.57
Cash from Investing -146.74
Cash from Financing -387.59
Net change in Cash -228.33
Free Cash Flow 622.36
Particulars MAR 2022 (Values in Cr)
Net Income 564.92
Cash from Operations 735.75
Cash from Investing -122.22
Cash from Financing -78.79
Net change in Cash 396.56
Free Cash Flow 867.92
Particulars MAR 2021 (Values in Cr)
Net Income 470.94
Cash from Operations 496.67
Cash from Investing -68.73
Cash from Financing -213.78
Net change in Cash 105.59
Free Cash Flow 564.67
Particulars MAR 2020 (Values in Cr)
Net Income 421.06
Cash from Operations 287.54
Cash from Investing -50.51
Cash from Financing -136.55
Net change in Cash 7.93
Free Cash Flow 338.70
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 21.20 2.15 302.17 34.11 / 77.70
BLISS GVS PHARMA LTD 126.30 16.55 1.31 1330.83 92.25 / 184.95
CIPLA LTD 1551.30 25.11 4.41 125285.64 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 289.65 24.00 2.93 852.47 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2916.75 57.85 29.54 49411.50 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 23.75 6.70 302.17 34.11 / 77.70
AMRUTAJAN HEALTH LTD 672.50 39.42 6.52 1944.24 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8961.95 133.66 32.97 22404.88 5000.00 / 9199.00
BLISS GVS PHARMA LTD 126.30 16.40 1.29 1330.83 92.25 / 184.95

ALIVUS LIFE SCIENCES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1011.20 -2.16 redarrow
red-green-graph indicator
11 Bearish
5 Bullish
  • 5 Days 1020.30
  • 26 Days 1021.60
  • 10 Days 1014.20
  • 50 Days 1034.20
  • 12 Days 1014.20
  • 100 Days 1043.10
  • 20 Days 1017.90
  • 200 Days 1011.50
1027.07 PIVOT

First Support

1015.13

First Resistance

1040.03

Second Support

1002.17

Second Resistance

1051.97

Third Support

990.23

Third Resistance

1064.93

RSI

51.72

ADX

11.50

MACD

-7.33

Williams % R

-24.75

Commodity Channel Index (CCI)

22.18

Date

2025-04-24

Week

34383.00

Same Day

25339.00

Month

50222.00

1 Year

0.57

3 Year

0.52

Over 1 Month

-3.24%

down

Over 1 Year

23.63%

down

Over 3 Months

-8.78%

down

Over 3 Years

26.51%

down

Over 6 Months

-12.12%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ALIVUS LIFE SCIENCES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
13.24%
Promoter Holdings
74.99%
FII
6.57%
DII
5.18%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nirma Limited 9.1896285E7 (74.99%) Shareholding of Promoter and Promoter Group
Polar Capital Funds Plc - Healthcare Opportunities 3423757.0 (2.79%) Public Shareholding
Quant Mutual Fund - Quant Small Cap Fund 2342299.0 (1.91%) Public Shareholding
Massachusetts Institute Of Technology 1504000.0 (1.23%) Public Shareholding

News

Left Arrow
Right Arrow

ALIVUS LIFE SCIENCES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Oct 2023 22.5 Interim 17 Oct 2023 Equity shares
24 Mar 2023 21.0 Interim 24 Mar 2023 Equity shares
15 Sep 2022 10.5 Final 17 Sep 2022 Equity shares
22 Nov 2021 10.5 Interim 23 Nov 2021 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Oct 2023 22.5 Interim 17 Oct 2023 Equity shares
24 Mar 2023 21.0 Interim 24 Mar 2023 Equity shares
15 Sep 2022 10.5 Final 17 Sep 2022 Equity shares
22 Nov 2021 10.5 Interim 23 Nov 2021 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ALIVUS LIFE SCIENCES LTD Share Price

Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018. A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs).

In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL.

The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023.

The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021.

Parent organization Indian Private
NSE symbol ALIVUS
Founded 2011
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Alivus Life Sciences Ltd?

Answer Field

The share price of Alivus Life Sciences Ltd for NSE is ₹ 1023.9 and for BSE is ₹ 1018.

What is the Market Cap of Alivus Life Sciences Ltd?

Answer Field

The market cap of Alivus Life Sciences Ltd for NSE is ₹ 1,23,90.90 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Alivus Life Sciences Ltd?

Answer Field

The 52 Week High and Low of Alivus Life Sciences Ltd for NSE is ₹ 1335.10 and ₹ 743.85 and for BSE is ₹ 1335.00 and ₹ 743.60.

How to Buy Alivus Life Sciences Ltd share?

Answer Field

You can trade in Alivus Life Sciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Alivus Life Sciences Ltd?

Answer Field

The 1 year returns on the stock has been 25.05%.

What is the Current Share Price of Alivus Life Sciences Ltd?

Answer Field

Alivus Life Sciences Ltd share price is for NSE ₹ 1023.9 & for BSE ₹ 1018 as on Apr 25 2025 11:15 AM.

What is the Market Cap of Alivus Life Sciences Ltd Share?

Answer Field

The market cap of Alivus Life Sciences Ltd for NSE ₹ 1,23,90.90 & for BSE ₹ 0.0 as on Apr 25 2025 11:15 AM.

What is the P/E Ratio of Alivus Life Sciences Ltd Share?

Answer Field

As on Apr 25 2025 11:15 AM the price-to-earnings (PE) ratio for Alivus Life Sciences Ltd share is 28.58.

What is the PB ratio of Alivus Life Sciences Ltd Share?

Answer Field

As on Apr 25 2025 11:15 AM, the price-to-book (PB) ratio for Alivus Life Sciences Ltd share is 207.16.

How to Buy Alivus Life Sciences Ltd Share?

Answer Field

You can trade in Alivus Life Sciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Alivus Life Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Alivus Life Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Alivus Life Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|